EEG-Neurofeedbacktraining in patients with ADHD at home - Group 3: Alternative training
Not Applicable
- Conditions
- F98.8Disturbance of activity and attentionHyperkinetic conduct disorderOther hyperkinetic disordersF90.0F90.1F90.8F90.9Hyperkinetic disorder, unspecifiedOther specified behavioural and emotional disorders with onset usually occurring in childhood and adolescence
- Registration Number
- DRKS00006076
- Lead Sponsor
- Klinik für Psychiatrie, Psychosomatik und Psychotherapie des Kindes- und Jugendalters, Universitätsklinikum RWTH Aachen, LFG Translationale Hirnforschung in Psychiatrie und Neurologie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Diagnosis of ADHD, co-morbid conduct disorder will be tolerated.
Exclusion Criteria
Epilepsy, treatment with neuroleptic medications at the time of the study, IQ below 80
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assesment of attentional performance (assessed with neuropsychological tests for attentional performance, subtests of the testbattery for attentional performance), assessed before and after completion of the neurofeedback training and after follow-up (approx. 6 months after completion of training). Used tasks: TAP (Testbatterie zur Aufmerksamkeitsprüfung), ANT (Amsterdam Neuropsychological Tasks).
- Secondary Outcome Measures
Name Time Method Clinical symptoms (Child Behavior Checklist), assessed before and after completion of the neurofeedback training and after follow-up (approx. 6 months after completion of training)
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does home-based EEG neurofeedback in DRKS00006076 alter neural plasticity in ADHD subtypes F90.0-F90.9?
What is the efficacy of DRKS00006076's alternative neurofeedback compared to methylphenidate in ADHD treatment?
Which EEG biomarkers predict response to home-based neurofeedback in DRKS00006076 ADHD patients?
What adverse events are associated with DRKS00006076's home-based EEG training and how are they managed?
How does DRKS00006076's neurofeedback compare to other non-pharmacological ADHD interventions like CBT?